{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:46:56Z","timestamp":1790066816201,"version":"4.0.1"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (cohort)<\/jats:p>\n                    <jats:p>Level of Evidence\u20032a<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Despite expanding treatment options for castration\u2010resistant prostate cancer (CRPC), therapies with long response duration remain intangible due to prostate cancer cells\u2019 natural ability to develop iterative resistance. Androgen receptor (AR) signaling has been shown to play a critical role in CRPC and its expression is regulated by the PI3K\u2010Akt pathway. Thus inhibition of AR signalling and PI3K\u2010Akt\u2010mTOR (a downstream mediator of the PI3K\u2010Akt pathway) pathway is a logical combination in CRPC and we report a phase II trial of RAD001 and bicalutamide.<\/jats:p>\n                    <jats:p>Our study is the first clinical trial report of an AR inhibitor of PI3K\u2010Akt\u2010mTOR. The AR pathway and the PI3K\u2010Akt\u2010mTOR pathway are two of the most relevant growth pathway for CRPC. Despite low efficacy results from our trial there will be significant interest in the field for these data (dose, schedule, response, toxicity, trial design) as newer generations of both AR inhibitors and PI3K\u2010Akt\u2010mTOR inhibitors are in development and likely will be tested in combination in CRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To determine best overall response and duration of response of RAD001, a selective inhibitor of mammalian target of rapamycin, in combination with bicalutamide in castration\u2010resistant prostate cancer (CRPC).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>To characterize the toxicity profile of RAD001 in combination with bicalutamide in patients with CRPC.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>A phase II study was conducted to explore the efficacy and tolerability of RAD001 (10\u2003mg daily) in combination with bicalutamide (50\u2003mg daily) in men with progressive CRPC.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The primary endpoint was a composite of prostate\u2010specific antigen (PSA) level and measurable disease response by standard criteria.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This single\u2010stage trial with a sample size of 38 eligible patients provided 90% power to differentiate a response rate of \u226540% from a response rate of \u226420%, as expected for bicalutamide alone (\u03b1= 0.10, power = 0.90).<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In total, 36 men were enrolled, with a median (range) age of 68 (60\u201372)\u2003years and median (range) baseline PSA level of 22.2\u2003(8.4\u2013121.3)\u2003ng\/mL, and 89% had metastatic disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>There were 31 (86%) patients had previously used bicalutamide for a median duration of 7.4 months.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>There were two patients with a confirmed PSA level decline \u226550%.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The median (interquartile range) time to progression was 8.7 (7.9\u201315.9)\u2003weeks.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The most common toxicity was grade 1\/2 mucositis, which was observed in 20 (56%) patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>The combination of RAD001 and bicalutamide in men with CRPC was well tolerated but had low activity and failed to achieve the primary endpoint of improved response compared to the results previously achieved for bicalutamide alone in this population.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11456.x","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T06:25:15Z","timestamp":1346221515000},"page":"1729-1735","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Phase II trial of RAD001 and bicalutamide for castration\u2010resistant prostate cancer"],"prefix":"10.1111","volume":"110","author":[{"given":"Mari","family":"Nakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Buckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Bubley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Weckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Elfiky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary\u2010Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0765"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.102"},{"key":"e_1_2_7_4_2","first-page":"2511","article-title":"Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist","volume":"59","author":"Taplin ME","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505253322101"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2011.06.006"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01010-X"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64039-4"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2928"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4000"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-10-0339"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0532"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00248-4"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605882"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.318"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4472"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3411"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.008"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj20020585"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0497-356"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5308.1943"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.8.4240"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.026"},{"key":"e_1_2_7_25_2","first-page":"145","article-title":"The role of PTEN in the progression and survival of prostate cancer","volume":"28","author":"Deocampo ND","year":"2003","journal-title":"Minerva Endocrinol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1362"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.995802"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2057"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1314"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1052"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171060098"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171076798"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4385"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3531"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.05.008"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04869"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5482"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0668"},{"key":"e_1_2_7_46_2","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K\u2010dependent feedback loop in human cancer","volume":"118","author":"Carracedo A","year":"2008","journal-title":"J Clin Invest"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4322"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh388"},{"key":"e_1_2_7_50_2","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Grunwald V","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.42"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm972"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.02.014"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11456.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11456.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:21:51Z","timestamp":1761758511000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11456.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11456.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11456.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]},"assertion":[{"value":"2012-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}